140 related articles for article (PubMed ID: 20354819)
1. Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population.
Ping G; Hui-Min W; Wei-Min W; Bao-Hui H
Med Oncol; 2011 Jun; 28(2):578-83. PubMed ID: 20354819
[TBL] [Abstract][Full Text] [Related]
2. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Socinski MA; Novello S; Brahmer JR; Rosell R; Sanchez JM; Belani CP; Govindan R; Atkins JN; Gillenwater HH; Pallares C; Tye L; Selaru P; Chao RC; Scagliotti GV
J Clin Oncol; 2008 Feb; 26(4):650-6. PubMed ID: 18235126
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer.
Novello S; Scagliotti GV; Rosell R; Socinski MA; Brahmer J; Atkins J; Pallares C; Burgess R; Tye L; Selaru P; Wang E; Chao R; Govindan R
Br J Cancer; 2009 Nov; 101(9):1543-8. PubMed ID: 19826424
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial.
Reynolds C; Spira AI; Gluck L; Bradie-Muller SJ; Zhan F; Boehm KA; Asmar L
Invest New Drugs; 2013 Oct; 31(5):1330-8. PubMed ID: 23761052
[TBL] [Abstract][Full Text] [Related]
5. CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.
Heist RS; Wang X; Hodgson L; Otterson GA; Stinchcombe TE; Gandhi L; Villalona-Calero MA; Watson P; Vokes EE; Socinski MA;
J Thorac Oncol; 2014 Feb; 9(2):214-21. PubMed ID: 24419419
[TBL] [Abstract][Full Text] [Related]
6. The evaluation of efficacy and safety of sunitinib on EGFR-TKI pretreated advanced non-small cell lung cancer patients in China.
Liu YR; Zhu W; Zhang JL; Huang JQ; Zhao YZ; Zhang W; Han BH; Yao YH; Jiang LY; Li SQ
Clin Respir J; 2014 Apr; 8(2):206-12. PubMed ID: 24118906
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer.
Waqar SN; Gopalan PK; Williams K; Devarakonda S; Govindan R
Chemotherapy; 2013; 59(1):8-13. PubMed ID: 23635552
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
9. The current status and evolving role of sunitinib in non-small cell lung cancer.
Socinski MA
J Thorac Oncol; 2008 Jun; 3(6 Suppl 2):S119-23. PubMed ID: 18520293
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
11. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
Baggstrom MQ; Socinski MA; Wang XF; Gu L; Stinchcombe TE; Edelman MJ; Baker S; Feliciano J; Novotny P; Hahn O; Crawford JA; Vokes EE
J Thorac Oncol; 2017 May; 12(5):843-849. PubMed ID: 28161554
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
13. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases.
Novello S; Camps C; Grossi F; Mazieres J; Abrey L; Vernejoux JM; Thall A; Patyna S; Usari T; Wang Z; Chao RC; Scagliotti G
J Thorac Oncol; 2011 Jul; 6(7):1260-6. PubMed ID: 21610524
[TBL] [Abstract][Full Text] [Related]
16. China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.
Zhou M; Chen X; Zhang H; Xia L; Tong X; Zou L; Hao R; Pan J; Zhao X; Chen D; Song Y; Qi Y; Tang L; Liu Z; Gao R; Shi Y; Yang Z
Cancer Commun (Lond); 2019 Jun; 39(1):36. PubMed ID: 31221221
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.
Han JY; Kim HY; Lim KY; Han JH; Lee YJ; Kwak MH; Kim HJ; Yun T; Kim HT; Lee JS
Lung Cancer; 2013 Feb; 79(2):137-42. PubMed ID: 23182663
[TBL] [Abstract][Full Text] [Related]
19. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Curigliano G; Pivot X; Cortés J; Elias A; Cesari R; Khosravan R; Collier M; Huang X; Cataruozolo PE; Kern KA; Goldhirsch A
Breast; 2013 Oct; 22(5):650-6. PubMed ID: 23958375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
